BiotechTube

Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

Conditions

Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

Trial Timeline

Mar 8, 2012 → Apr 8, 2024

NCT ID
NCT01550003

About Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP)

Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP) is a phase 3 stage product being developed by UCB for Polyarticular-course Juvenile Idiopathic Arthritis (JIA). The current trial status is completed. This product is registered under clinical trial identifier NCT01550003. Target conditions include Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01550003Phase 3Completed